These formulations were demonstrated to significantly decrease the occurrence of radiation pneumonitis and progress clinical radiographic physiologic (CRP) dyspnea score and the Radiation Therapy Oncology Group (RTOG) grading score, in the allocated NSCLC patients who were under the treatment of radiotherapy. This evidence concerns the gene CRP and non-small cell lung carcinoma.